ACR 2026 RheumNow ILD Topic Compilation b Save
Does Scl-Ab change predict pulmonary decline in systemic sclerosis
Use of JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease
Snippets & SNPs in ILD and Fibrosis
Interstitial Pneumonia with Autoimmune Features (IPAF)
Transcription
This is an ACR 2026 podcast coming to you from ACR in Orlando. Hope you enjoy it.
This Room Now podcast is brought to you with support from Boehringer Ingelheim. Boehringer Ingelheim is committed to advancing research in rheumatology through ongoing work in progressive pulmonary fibrosis, interstitial lung disease, and systemic autoimmune rheumatic diseases, including systemic sclerosis, myositis, and beyond. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies in areas of high unmet medical need. Boehringer Ingelheim is proud to support RheumNow and the rheumatology community. Thank you for listening.
Hello. This is Eric Dine with RheumNow at day one of ACR Convergence in Orlando, Florida. I'm gonna talk about abstract zero nine fifty four, presented by Eric Robbins et al from the CONCER consortium, looking at serum SCL 70 antibodies or anti topoisomerase antibodies, and the relevance of tracking them serially, to assess for of pulmonary decline. We generally think of looking at these antibodies as, binary, present or not present, usually not something that we're tracking over time. So is there any value in serially monitoring, their their levels?
They looked at eighty six patients who had an STL70 test from a commercial lab of them when they used their LIPs testing, is the luciferase immunoprecipitation systems, were able to confirm positivity in seventy four percent... Seventy four of the eighty five. Fifty four of these seventy four patients had ILD as compared to the twenty that did not have ILD. So we know that SEL70 is a risk factor for ILD, for diffuse skin, for progressive pulmonary decline, and a more severe disease phenotype and poorer prognoses. When they tracked them serially, they checked a baseline with their lips lab, and then they checked it again at six months and compared the results.
They then looked at the pulmonary function test between six months and twenty four months to see if it predicted any form of decline. When they looked at setting a threshold of a thirty percent increase in the SEL70 antibody, they did find that it predicted decline of their pulmonary function testing. So in the eighteen out of the forty six patients that were able to have an analysis, eighteen of forty six had that thirty percent increase, and of those patients, forty four percent of them progressed, as compared to fourteen percent were progressors in the non increased group. So that showed these patients with, the higher SEL70 increases, over time were more likely to have more progressive ILD. The hazard ratio for this is three point six seven.
They did not find significance for other markers like DLCO, other factors such as modified Rodnan Skin Score, physician assessed damage, were not found to be statistically significant. The authors do note that the cutoff was fairly arbitrary of doing that greater than 30% increase. When they looked at it more as a continuous variable, they did not meet significance, but this is, I think, basis for further investigation. Can we think of anti STL antibody as a dynamic, prognostic biomarker rather than one static point? And looking at it over time, I think, will provide us some more additional information.
For more information at, ACR Convergence, tune in to RheumNow for more coverage.
Hello. My name is Elena Jerns, and I'm reporting from Orlando, Florida. A lot of interest in JAK inhibitors in RAY ILD at this meeting. I'm glad to see the studies because we certainly need more. It does seem that JAK inhibitors are helpful in our reality based on a small meta analysis which was published in 2024.
But we have so many JAK inhibitors now and we are often limited by insurance companies in what we can prescribe. But are they truly interchangeable? Are they truly safe and efficacious in our ALD? Well, this meeting had several relevant posters. So poster number four seventy eight by doctor Munoz detailed results of a retrospective observational study of baricitinib in eighty four patients with RAILD.
They demonstrated stability of PFTs and improvement in dyspnea throughout follow-up, and importantly the steroid use was decreased. We of course don't know how their trajectory was prior to the treatment from the abstract, but the improvement in symptoms and reduction in steroids is encouraging regardless. Poster number four forty nine by Doctor. Kikuchi and colleagues also demonstrated that the array ILD was stable and even improved based on lung ultrasound scores with treatment with JAK inhibitors. They didn't specify the JAK inhibitors, unfortunately.
In poster seven zero three, Doctor. Ortiz and colleagues looked at 43 patients from Spain treated with upadacitinib and found stability or improvement in lung function parameters and again symptoms of dyspnea. Despite these promising results, JAK inhibitors are still not widely used in our RAYALDEE as per poster number four sixty two by Doctor. Sarmiento Monroy regarding real world treatment patterns in Array ILD. Their nested case control study from Spain showed that only three percent of patients with Array ILD were treated with JAK inhibitors, but eleven percent of patients with RA with no ILD at baseline were treated with JAK inhibitors.
Important safety signal for JAK inhibitor was accessed. I think the worry about cardiovascular safety precludes us often from prescribing JAK inhibitors in RA LD, as these patients are frequently dosed with many cardiovascular risk factors also. Poster number four forty one by Doctor. Kasiraj compared safety between JAK inhibitors and found that tofacitinib was associated with significantly higher risk compared to upadacitinib or baricitinib in terms of major cardiovascular events. And Doctor.
Kazuo's study in poster four forty two found that signal as well that tofacitinib but not upadacitinib was associated with higher risk of major cardiovascular events in a real world study. The multitude of studies of JAK inhibitors, and these are not even all the posters about them, support the use of JAK inhibitors in RYALD. Safety signals support going for baricitinib or upadacitinib in patients with RALD who have cardiovascular risk factors. And I would advocate for perhaps a randomized controlled trial, and specifically RALD using specific JAK inhibitors. It does seem like we're not using JAK inhibitors enough in RA ILD yet, but hopefully it will change with more data.
Thank you.
Hi. I'm doctor Janet Pope or tweeting as, at Janet Bourdeaux. I'm here at RheumNow at ACR twenty twenty six in Orlando, Florida. I wanted to talk about SNPs and snippets in interstitial lung disease related to our SARDs. So I'm gonna talk about three posters, zero zero one nine, zero zero three seven, and zero zero two five.
And they have some mechanisms of action in common and different pathways. So the first one, zero zero one nine, was looking at t l one a in sarcoidosis and looking at the fibrosis and sarcoidosis, which could be systemically all over, including in the lungs. And t l one a is a target for some, drug trials for pulmonary, interstitial lung disease. So what they found was t o one a was, abnormal in the myeloid cells and eventually in the cells that became and made granuloma. And so it would look like it's something important on causation.
And what they found was t o one a was affecting TNF, I o one beta, I o six, and I o 17. And they're all cytokines you're very familiar with in inflammatory arthritis as a for instance. So I think this might mechanistically give us an idea of upstream and downstream, areas for interstitial lung disease or fibrosis that we might be able to target. The next one was looking at zero zero three seven, the poster, and it was looking at scleroderma ILD, and they wanted to look at correlations with baseline FVC, so forced vital capacity. And it was actually FVC percent predicted.
So they did a whole array on 60 patients with scleroderma ILD and nineteen with scleroderma no ILD, and they kind of matched those patients. And what they found was predictive at baseline, but not of worsening over time. So both an elevated k... KL six and an abnormal ICAM one were both important for low FVC at the beginning. However, the holy grail in scleroderma ILD is predicting who might have upregulated things that might actually, might actually show that we can predict what's gonna happen in scleroderma ILD.
The final one was from UCSF. It's 0025, and it was looking at some similarities comparing and contrasting SARD ILD and progressive pulmonary fibrosis, including IPF. So it's been known to them, and I guess now to me, is that short telomeres are a big deal in, IPF that they're often present, and I think they're correlated with worth... Worse IPF. And some people are even ordering telomeres more for research purposes.
So what they wanted to look at was senescence with epithelial remodeling that would be bad remodeling. And what they found was that DNA damage was quite common in the patients with ILD and the SARDs, the systemic autoimmune rheumatic diseases, and also in IPF. Why did I choose this poster is because I think it's yet another pathway to say if there's abnormal senescence, is there ways of changing that that we could modify or decrease the chance of someone with SARD ILD going to fibrosis? So I hope these snippets that I, got from posters will be helpful to you in understanding ILD of the SARDs. Thank you.
Hello. My name is Elena Jerns, and I'm reporting from ACR twenty twenty six in Orlando, Florida. I will say that as an ILD focused rheumatologist, I'm a little disappointed with the lack of ILD specific scientific sessions this year. Although the ones that I have been to have been excellent, and I was pleased that there were several posters on IPAF. IPAF, if you remember, is interstitial pneumonia without immune features.
It is characterized by ILD, and autoimmune features such as Raynaud's, inflammatory arthritis, positive serologies, etcetera, etcetera. We can talk about this another time, about the definition of IPAF. But it is largely still a research classification, and as a result, there are not a ton of studies on it, and definitely no population based studies. Most studies of IPAF are limited to tertiary referral centers and retrospective cohort studies. IPAF is very hard to understand and characterize, and there is much unknown regarding its natural course, prognosis, etiology, and optimal treatment.
There are thoughts that IPAF may be a glorified idiopathic pulmonary fibrosis with positive antibodies, especially for those subtypes with usual interstitial pneumonia pattern. Others wonder whether this is a systemic autoimmune rheumatic disease, or SARD, confined to the lung. And then maybe yet another subtype, maybe simply an early SARD that is in the lung, and will eventually develop into a defined SARD. And this is an important question, because if it is something like an early SARD, should we be immunosuppressing these people to prevent it? Should we assume that these people have that SARD even before they get it?
Well, few researchers from Texas Tech mostly decided to do just that, to figure out if IPAP progresses to SARD, and if so, which kinds of IPAF progress and to which diseases. Poster number six eighty three by doctor Shotelersok looked at the likelihood of progression from IPAF to start ILDs via systematic review and meta analysis. They found eight studies that looked at that question. In those studies, presence of IPAF within cohorts of interstitial pneumonia was associated with seven times higher odds of progression to a SAARD, most commonly scleroderma and rheumatoid arthritis. They did not unfortunately present any conclusions regarding the timing of that progression.
Then poster number sixteen thirty by doctor Sodstri, also from Texas Tech, looked at predictors of that progression in a meta analysis. They included four studies this time from the eight included in the project by doctor Shotel Ersuch. They found that those who progressed to start were younger and the presence of SCL 70 antibody, Mechanics hands, and organizing pneumonia were predictors of progression to start in iPath. To me, those last two characteristics sound like some sort of myositis ILD subtype. Since most of the studies included were retrospective, it is hard to know whether all those patients had a full set of myositis antibodies checked.
These studies were much needed. The natural course of IPAF is poorly understood. And I think their systematic review emphasized that there is still a gap in how we design studies in IPAF. There are a lot more studies than eight in IPAF, and the fact that only eight studies looked at progression to SAARD tells me that we're not looking at that question specifically. We need more prospective studies so that we can definitively track who developed SARD and when, and we need to make sure that any patient that we're evaluating with ILD gets deep phenotyping, and that includes a wide range of antibodies, so that we later can know better and understand which features truly predict that star development and progression.
Thank you.
This Room Now podcast is brought to you with support from Boehringer Ingelheim. Boehringer Ingelheim is committed to advancing research in rheumatology through ongoing work in progressive pulmonary fibrosis, interstitial lung disease, and systemic autoimmune rheumatic diseases, including systemic sclerosis, myositis, and beyond. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies in areas of high unmet medical need. Boehringer Ingelheim is proud to support RheumNow and the rheumatology community. Thank you for listening.
Hello. This is Eric Dine with RheumNow at day one of ACR Convergence in Orlando, Florida. I'm gonna talk about abstract zero nine fifty four, presented by Eric Robbins et al from the CONCER consortium, looking at serum SCL 70 antibodies or anti topoisomerase antibodies, and the relevance of tracking them serially, to assess for of pulmonary decline. We generally think of looking at these antibodies as, binary, present or not present, usually not something that we're tracking over time. So is there any value in serially monitoring, their their levels?
They looked at eighty six patients who had an STL70 test from a commercial lab of them when they used their LIPs testing, is the luciferase immunoprecipitation systems, were able to confirm positivity in seventy four percent... Seventy four of the eighty five. Fifty four of these seventy four patients had ILD as compared to the twenty that did not have ILD. So we know that SEL70 is a risk factor for ILD, for diffuse skin, for progressive pulmonary decline, and a more severe disease phenotype and poorer prognoses. When they tracked them serially, they checked a baseline with their lips lab, and then they checked it again at six months and compared the results.
They then looked at the pulmonary function test between six months and twenty four months to see if it predicted any form of decline. When they looked at setting a threshold of a thirty percent increase in the SEL70 antibody, they did find that it predicted decline of their pulmonary function testing. So in the eighteen out of the forty six patients that were able to have an analysis, eighteen of forty six had that thirty percent increase, and of those patients, forty four percent of them progressed, as compared to fourteen percent were progressors in the non increased group. So that showed these patients with, the higher SEL70 increases, over time were more likely to have more progressive ILD. The hazard ratio for this is three point six seven.
They did not find significance for other markers like DLCO, other factors such as modified Rodnan Skin Score, physician assessed damage, were not found to be statistically significant. The authors do note that the cutoff was fairly arbitrary of doing that greater than 30% increase. When they looked at it more as a continuous variable, they did not meet significance, but this is, I think, basis for further investigation. Can we think of anti STL antibody as a dynamic, prognostic biomarker rather than one static point? And looking at it over time, I think, will provide us some more additional information.
For more information at, ACR Convergence, tune in to RheumNow for more coverage.
Hello. My name is Elena Jerns, and I'm reporting from Orlando, Florida. A lot of interest in JAK inhibitors in RAY ILD at this meeting. I'm glad to see the studies because we certainly need more. It does seem that JAK inhibitors are helpful in our reality based on a small meta analysis which was published in 2024.
But we have so many JAK inhibitors now and we are often limited by insurance companies in what we can prescribe. But are they truly interchangeable? Are they truly safe and efficacious in our ALD? Well, this meeting had several relevant posters. So poster number four seventy eight by doctor Munoz detailed results of a retrospective observational study of baricitinib in eighty four patients with RAILD.
They demonstrated stability of PFTs and improvement in dyspnea throughout follow-up, and importantly the steroid use was decreased. We of course don't know how their trajectory was prior to the treatment from the abstract, but the improvement in symptoms and reduction in steroids is encouraging regardless. Poster number four forty nine by Doctor. Kikuchi and colleagues also demonstrated that the array ILD was stable and even improved based on lung ultrasound scores with treatment with JAK inhibitors. They didn't specify the JAK inhibitors, unfortunately.
In poster seven zero three, Doctor. Ortiz and colleagues looked at 43 patients from Spain treated with upadacitinib and found stability or improvement in lung function parameters and again symptoms of dyspnea. Despite these promising results, JAK inhibitors are still not widely used in our RAYALDEE as per poster number four sixty two by Doctor. Sarmiento Monroy regarding real world treatment patterns in Array ILD. Their nested case control study from Spain showed that only three percent of patients with Array ILD were treated with JAK inhibitors, but eleven percent of patients with RA with no ILD at baseline were treated with JAK inhibitors.
Important safety signal for JAK inhibitor was accessed. I think the worry about cardiovascular safety precludes us often from prescribing JAK inhibitors in RA LD, as these patients are frequently dosed with many cardiovascular risk factors also. Poster number four forty one by Doctor. Kasiraj compared safety between JAK inhibitors and found that tofacitinib was associated with significantly higher risk compared to upadacitinib or baricitinib in terms of major cardiovascular events. And Doctor.
Kazuo's study in poster four forty two found that signal as well that tofacitinib but not upadacitinib was associated with higher risk of major cardiovascular events in a real world study. The multitude of studies of JAK inhibitors, and these are not even all the posters about them, support the use of JAK inhibitors in RYALD. Safety signals support going for baricitinib or upadacitinib in patients with RALD who have cardiovascular risk factors. And I would advocate for perhaps a randomized controlled trial, and specifically RALD using specific JAK inhibitors. It does seem like we're not using JAK inhibitors enough in RA ILD yet, but hopefully it will change with more data.
Thank you.
Hi. I'm doctor Janet Pope or tweeting as, at Janet Bourdeaux. I'm here at RheumNow at ACR twenty twenty six in Orlando, Florida. I wanted to talk about SNPs and snippets in interstitial lung disease related to our SARDs. So I'm gonna talk about three posters, zero zero one nine, zero zero three seven, and zero zero two five.
And they have some mechanisms of action in common and different pathways. So the first one, zero zero one nine, was looking at t l one a in sarcoidosis and looking at the fibrosis and sarcoidosis, which could be systemically all over, including in the lungs. And t l one a is a target for some, drug trials for pulmonary, interstitial lung disease. So what they found was t o one a was, abnormal in the myeloid cells and eventually in the cells that became and made granuloma. And so it would look like it's something important on causation.
And what they found was t o one a was affecting TNF, I o one beta, I o six, and I o 17. And they're all cytokines you're very familiar with in inflammatory arthritis as a for instance. So I think this might mechanistically give us an idea of upstream and downstream, areas for interstitial lung disease or fibrosis that we might be able to target. The next one was looking at zero zero three seven, the poster, and it was looking at scleroderma ILD, and they wanted to look at correlations with baseline FVC, so forced vital capacity. And it was actually FVC percent predicted.
So they did a whole array on 60 patients with scleroderma ILD and nineteen with scleroderma no ILD, and they kind of matched those patients. And what they found was predictive at baseline, but not of worsening over time. So both an elevated k... KL six and an abnormal ICAM one were both important for low FVC at the beginning. However, the holy grail in scleroderma ILD is predicting who might have upregulated things that might actually, might actually show that we can predict what's gonna happen in scleroderma ILD.
The final one was from UCSF. It's 0025, and it was looking at some similarities comparing and contrasting SARD ILD and progressive pulmonary fibrosis, including IPF. So it's been known to them, and I guess now to me, is that short telomeres are a big deal in, IPF that they're often present, and I think they're correlated with worth... Worse IPF. And some people are even ordering telomeres more for research purposes.
So what they wanted to look at was senescence with epithelial remodeling that would be bad remodeling. And what they found was that DNA damage was quite common in the patients with ILD and the SARDs, the systemic autoimmune rheumatic diseases, and also in IPF. Why did I choose this poster is because I think it's yet another pathway to say if there's abnormal senescence, is there ways of changing that that we could modify or decrease the chance of someone with SARD ILD going to fibrosis? So I hope these snippets that I, got from posters will be helpful to you in understanding ILD of the SARDs. Thank you.
Hello. My name is Elena Jerns, and I'm reporting from ACR twenty twenty six in Orlando, Florida. I will say that as an ILD focused rheumatologist, I'm a little disappointed with the lack of ILD specific scientific sessions this year. Although the ones that I have been to have been excellent, and I was pleased that there were several posters on IPAF. IPAF, if you remember, is interstitial pneumonia without immune features.
It is characterized by ILD, and autoimmune features such as Raynaud's, inflammatory arthritis, positive serologies, etcetera, etcetera. We can talk about this another time, about the definition of IPAF. But it is largely still a research classification, and as a result, there are not a ton of studies on it, and definitely no population based studies. Most studies of IPAF are limited to tertiary referral centers and retrospective cohort studies. IPAF is very hard to understand and characterize, and there is much unknown regarding its natural course, prognosis, etiology, and optimal treatment.
There are thoughts that IPAF may be a glorified idiopathic pulmonary fibrosis with positive antibodies, especially for those subtypes with usual interstitial pneumonia pattern. Others wonder whether this is a systemic autoimmune rheumatic disease, or SARD, confined to the lung. And then maybe yet another subtype, maybe simply an early SARD that is in the lung, and will eventually develop into a defined SARD. And this is an important question, because if it is something like an early SARD, should we be immunosuppressing these people to prevent it? Should we assume that these people have that SARD even before they get it?
Well, few researchers from Texas Tech mostly decided to do just that, to figure out if IPAP progresses to SARD, and if so, which kinds of IPAF progress and to which diseases. Poster number six eighty three by doctor Shotelersok looked at the likelihood of progression from IPAF to start ILDs via systematic review and meta analysis. They found eight studies that looked at that question. In those studies, presence of IPAF within cohorts of interstitial pneumonia was associated with seven times higher odds of progression to a SAARD, most commonly scleroderma and rheumatoid arthritis. They did not unfortunately present any conclusions regarding the timing of that progression.
Then poster number sixteen thirty by doctor Sodstri, also from Texas Tech, looked at predictors of that progression in a meta analysis. They included four studies this time from the eight included in the project by doctor Shotel Ersuch. They found that those who progressed to start were younger and the presence of SCL 70 antibody, Mechanics hands, and organizing pneumonia were predictors of progression to start in iPath. To me, those last two characteristics sound like some sort of myositis ILD subtype. Since most of the studies included were retrospective, it is hard to know whether all those patients had a full set of myositis antibodies checked.
These studies were much needed. The natural course of IPAF is poorly understood. And I think their systematic review emphasized that there is still a gap in how we design studies in IPAF. There are a lot more studies than eight in IPAF, and the fact that only eight studies looked at progression to SAARD tells me that we're not looking at that question specifically. We need more prospective studies so that we can definitively track who developed SARD and when, and we need to make sure that any patient that we're evaluating with ILD gets deep phenotyping, and that includes a wide range of antibodies, so that we later can know better and understand which features truly predict that star development and progression.
Thank you.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.